COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621000714886
Ethics application status
Approved
Date submitted
5/05/2021
Date registered
8/06/2021
Date last updated
8/06/2021
Date data sharing statement initially provided
8/06/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
The effects of 3FDC dietary supplementation on psychological functioning in an adult population
Scientific title
The effects of 3FDC dietary supplementation on psychological functioning in an adult population with moderate depression, anxiety or stress symptoms
Secondary ID [1] 304135 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Psychological Health 321826 0
Depression 321827 0
Anxiety 321828 0
Stress 322232 0
Gut Function 322233 0
Biochemical Health 322234 0
Condition category
Condition code
Mental Health 319558 319558 0 0
Other mental health disorders
Mental Health 319559 319559 0 0
Studies of normal psychology, cognitive function and behaviour
Mental Health 319925 319925 0 0
Anxiety
Mental Health 319926 319926 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Active Intervention: Dosed with oral 3FDC mini-tablets, equivalent to 1200 mg sodium butyrate, twice a day for 6 weeks.

Compliance will be monitored throughout the study. Participants will complete a daily online log via a mobile application (app) during the 6-week intervention period to assess protocol compliance or a weekly log for those participants who choose to complete the paper-based version instead of the mobile app. Any queries from the logs will be followed up via a phone call. Participants who consume less than 80% of the required product in a given fortnight will receive a courtesy call from site study staff to problem solve compliance issues. Subjects will be instructed to bring back any remaining product to site for accountability purposes.
Intervention code [1] 320474 0
Treatment: Drugs
Comparator / control treatment
Placebo Control: Dosed with oral matching placebo twice a day for 6 weeks. The placebo will be comprised of microcrystalline cellulose coated in the same enteric coating as the treatment.
Control group
Placebo

Outcomes
Primary outcome [1] 327421 0
Change in Hospital Anxiety and Depression Scale (HADS) anxiety and depression subscale scores
Timepoint [1] 327421 0
Baseline, 2 weeks, 4 weeks and 6 weeks (primary timepoint) after intervention commencement
Secondary outcome [1] 395070 0
Change in psychological health assessed using the Depression and Anxiety Stress Scale (DASS-21; subscale scores on the depression, anxiety and stress symptom domains)
Timepoint [1] 395070 0
Baseline, 2 weeks, 4 weeks and 6 weeks after intervention commencement
Secondary outcome [2] 395071 0
Change in psychological health assessed using the Perceived Stress Scale (PSS)
Timepoint [2] 395071 0
Baseline, 2 weeks, 4 weeks and 6 weeks after intervention commencement
Secondary outcome [3] 395072 0
Change in psychological health assessed using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
Timepoint [3] 395072 0
Baseline, 2 weeks, 4 weeks and 6 weeks after intervention commencement
Secondary outcome [4] 395073 0
Change in psychological health assessed using the Penn State Worry Questionnaire (PSWQ)
Timepoint [4] 395073 0
Baseline, 2 weeks, 4 weeks and 6 weeks after intervention commencement
Secondary outcome [5] 395074 0
Gut symptoms and intestinal comfort assessed using the Gastrointestinal Symptom Rating Scale (GSRS)
Timepoint [5] 395074 0
Baseline, 2 weeks, 4 weeks and 6 weeks after intervention commencement
Secondary outcome [6] 395075 0
Changes in vagus nerve activity as indicated by resting heart rate variability using a finger sensor monitor
Timepoint [6] 395075 0
Baseline and 6 weeks after intervention commencement
Secondary outcome [7] 395076 0
Changes in habitual dietary intake (total intake, macro- and micro-nutrient intake) assessed using 24-hour weighed food records
Timepoint [7] 395076 0
Baseline and 6 weeks after intervention commencement
Secondary outcome [8] 395077 0
Vital signs using measures of blood pressure assessed with a clinical grade automated blood pressure machine, heart rate assessed with a finger sensor monitor, body temperature assessed with a digital thermometer, and respiratory rate assessed by counting the number of times the chest rises per minute while at rest,
Timepoint [8] 395077 0
Baseline and 6 weeks after intervention commencement
Secondary outcome [9] 395078 0
Biochemical safety parameters as assessed by a blood sample, including: aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), lactate dehyrogenase (LD), creatinine, creatinine kinase, urea nitrogen, sodium, potassium, chloride, bicarbonate, urea, calcium, C-reactive protein (CRP), uric acid, phosphate, albumin, globulins, protein, total bilirubin, glucose
Timepoint [9] 395078 0
Baseline and 6 weeks after intervention commencement
Secondary outcome [10] 395079 0
Haematological safety parameters as assessed by a blood sample, including: haemoglobin, red blood cell count (RBC), red cell distribution (RDW), packed cell volume (PCV), mean cell volume (MCV), mean cell hemoglobin concentration (MCHC), platelets, white cell count (WCC), neutrophils, lymphocytes, monocytes, eosinophils, basophils
Timepoint [10] 395079 0
Baseline and 6 weeks after intervention commencement
Secondary outcome [11] 395086 0
Incidence of participant reported serious adverse events and adverse events assessed in accordance with the International Conference on Harmonisation Good Clinical Practice (ICH-GCP) guidelines.
Timepoint [11] 395086 0
Baseline and 6 weeks after intervention commencement
Secondary outcome [12] 395087 0
Changes in use of concomitant medications assessed by participant self-report.
Timepoint [12] 395087 0
Baseline and 6 weeks after intervention commencement

Eligibility
Key inclusion criteria
1. Male or female aged greater than or equal to 18 years & <56 years inclusive
2. Moderate scores on at least one of the depression, anxiety or stress symptom domains measured by the DASS-21 confirmed at phone screening (score greater than or equal to 13 & less than or equal to 20 on the depression subscale; greater than or equal to 10 & less than or equal to 14 on the anxiety subscale; greater than or equal to 19 & less than or equal to 26 on the stress subscale)
3. Body mass index (BMI) >18.5 kg/m2 and less than or equal to 35 kg/m2 confirmed during phone screening and verified at enrollment
4. Willing to provide written Informed Consent
5. Access to a smartphone and willing to download a free application from the app store
6. Able to access own email address
Minimum age
18 Years
Maximum age
55 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Use of any of the following types of supplements within the past month and not prepared to abstain from use for the study duration:
• Supplements containing prebiotics or probiotics
• Fibre supplements (e.g. psyllium plant sterols, Metamucil, Benefibre)
2. Use of any of the following types of prescribed medications within the past 3 months and not prepared to abstain from use for the study duration
• Antidepressants
• Anxiolytics
• Narcotics
• Stimulants
• Anti-psychotics
• Antibiotics
• Systemic steroids (e.g. prednisolone)
• Chronic drug therapy that interferes with vitamin D metabolism, such as glucocorticoids (e.g. dexamethasone)
3. Currently seeking psychological treatment (e.g., psychotherapy, counselling)
4. Participation in nightshift work within the past month
5. Previous diagnosis of any of the following: cardiovascular disease, diabetes, cancer, hypercholesterolaemia, or kidney disease
6. Smoking (i.e. history of smoking within the last six months)
7. Women of childbearing potential (WOCBP) who:
a. Are not currently using effective methods of contraception and
b. Have not been using effective methods of contraception for the past 14 days and
c. Are not willing to use effective methods of contraception throughout the study
8. WOCBP who are currently pregnant or lactating
9. Aversion and/or intolerance/allergy to the study intervention products^
10. History of or known presence of substance use, endocrine, neurological, or psychiatric disorders, any surgical history (including, but not limited to brain surgery, coronary artery bypass surgery, other heart surgery, gastrointestinal surgery i.e., gastric banding, clinically significant conditions (i.e. renal or urological disease, liver disease, gastrointestinal disease [including, but not limited to diverticulitis, ulcerative colitis, Crohn’s disease, bowel cancer, or coeliac disease if not managed by a gluten free diet]) or any other significant disease) or organ dysfunction that in the opinion of the Principal Investigator may affect the participant’s ability to participate in the study or the study results
11. Currently hospitalised or any planned hospitalisations during the study that may affect the participant’s ability to comply with the study in the opinion of the Principal Investigator
12. Received an investigational drug within the past 3 months that in the opinion of the Principal Investigator may affect the applicant’s ability to participate in the study or the study results
13. Blood haematology and biochemistry test results outside the normal reference range at screening, in the opinion of the Principal Investigator
^the intervention product is not suitable for people with an allergy to cellulose

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
The National Health & Medical Research Council Clinical Trials Centre Central Randomisation Services using interactive voice response system (IVRS) will be engaged to implement independent randomisation for this study and treatment kit allocation. Following confirmation of eligibility and receipt of written consent, participants will be provided with a unique study identifier inclusive of the study site code. On attendance at the baseline visit, the PI (or designee) will telephone the automated NHMRC-IRVS and provide the participants study ID, sex, BMI, DASS score, and age enabling the system to randomly assign the participant to an intervention condition whilst balancing groups on these key variables. If a participant withdraws from the study or is unable to complete the study for any reason after being randomised, their Study ID and intervention allocation will not be reissued to a new participant.

NHMRC will be responsible for the allocation and concealment of which group each participant is allocated to. Study staff will be blinded to group allocations.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Eligible participants will be assigned to interventions using stratified random assignment based on study ID, sex, BMI, DASS score, and age. The randomisation scheme will be computer generated
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
N/A
Phase
Phase 1 / Phase 2
Type of endpoint(s)
Safety/efficacy
Statistical methods / analysis
It was calculated that a sample size of N=100 provides high power (~95%) to detect the minimal clinically important difference corresponding to a change greater than or equal to 1.5 points on the primary outcome, the Hospital Anxiety and Depression Scale (effect size Cohen’s f=.15; a=.05). This estimate allows for attrition of 15% after which, we would still have sufficient power (~90%) to detect an effect of the same magnitude.

There are no planned interim analyses of any study outcomes. Therefore, a full statistical analysis plan will be developed prior to completion of the study. The analysis plan will detail intention for both primary and secondary outcomes. It is envisaged that analysis will focus on generalised linear mixed models. Outcomes will be analysed on an intention to treat (ITT) and per protocol basis for all participants. Outcomes to be compared between the study groups include psychological wellness and mood, gut function, dietary intake, and biochemical outcomes. The primary analyses will involve 2-way comparisons between the active intervention and the placebo control group.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 308513 0
Commercial sector/Industry
Name [1] 308513 0
Anatara Lifesciences
Address [1] 308513 0
Level 3/62 Lygon St., Carlton, Melbourne VIC 3053, Australia
Country [1] 308513 0
Australia
Funding source category [2] 308515 0
Government body
Name [2] 308515 0
The Commonwealth of Australia represented by the Department of Industry, Science, Energy and Resources
Address [2] 308515 0
10 Binara Street, Canberra ACT 2600, Australia
Country [2] 308515 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Anatara Lifesciences
Address
Level 3/62 Lygon St., Carlton, Melbourne VIC 3053 Australia
Country
Australia
Secondary sponsor category [1] 309369 0
None
Name [1] 309369 0
Address [1] 309369 0
Country [1] 309369 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 308471 0
CSIRO Health and Medical Human Research Ethics Committee
Ethics committee address [1] 308471 0
Ecosciences Precinct, Dutton Park QLD 4102 GPO BOX 2583, Brisbane QLD 4001, Australia.
Ethics committee country [1] 308471 0
Australia
Date submitted for ethics approval [1] 308471 0
09/02/2021
Approval date [1] 308471 0
19/04/2021
Ethics approval number [1] 308471 0
2021_014_HREC

Summary
Brief summary
The aim of this study is to investigate the effects of a novel dietary supplement (3DFC) on psychological functioning and other health related outcomes including mood, wellbeing, biochemical parameters, heart rate variability and gut symptoms in adults aged 18-55 years with elevated stress, anxiety and depression symptoms. The 3DFC supplement developed by the principal trial sponsor (Anatara Lifesciences) contains elevated levels of sodium butryrate and is designed to be metabolised by the gut microbiota. The 3FDC supplement has the potential to produce benefits in the outcomes described. The CSIRO will lead a 6-week randomised, double-blind placebo-controlled trial consisting of two intervention arms: 1) the 3DFC dietary supplement; and 2) placebo control. It is expected that the 3FDC supplement will lead to a greater reduction in anxiety and depression subscale scores on the Hospital Anxiety and Depression Scale compared to a placebo over the 6 week period.
Trial website
CSIRO Adelaide: https://www.csiro.au/en/Research/Health/Nutrition-and-health-research-clinic/Current-studies/Participate-in-a-study
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 110806 0
Dr Ian Zajac
Address 110806 0
Research Scientist/Clinical Psychologist
Nutrition and Health Program, Health & Biosecurity, CSIRO
SAHMRI (South Australian Health and Medical Research Institute), North Terrace, Adelaide, South Australia 5000
Country 110806 0
Australia
Phone 110806 0
+61 8 8303 8875
Fax 110806 0
Email 110806 0
Ian.Zajac@csiro.au
Contact person for public queries
Name 110807 0
Dr Ian Zajac
Address 110807 0
Research Scientist/Clinical Psychologist
Nutrition and Health Program, Health & Biosecurity, CSIRO
SAHMRI (South Australian Health and Medical Research Institute), North Terrace, Adelaide, South Australia 5000
Country 110807 0
Australia
Phone 110807 0
+61 8 8303 8875
Fax 110807 0
Email 110807 0
Ian.Zajac@csiro.au
Contact person for scientific queries
Name 110808 0
Dr Ian Zajac
Address 110808 0
Research Scientist/Clinical Psychologist
Nutrition and Health Program, Health & Biosecurity, CSIRO
SAHMRI (South Australian Health and Medical Research Institute), North Terrace, Adelaide, South Australia 5000
Country 110808 0
Australia
Phone 110808 0
+61 8 8303 8875
Fax 110808 0
Email 110808 0
Ian.Zajac@csiro.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
No IPD sharing has been approved under the ethics approval for this study
What supporting documents are/will be available?
No other documents available
Summary results
No Results